Industry resources and insights

Sort by year

All time
2025
2024
2023
2022
2021
2020
2019 and older

Articles

13.10.2025

Surrogates Under Scrutiny: Proving the Link to Out...

Surrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...

Webinar

08.10.2025

Navigating NICE’s HST Pathway: Insights from Bot...

NICE’s Highly Specialised Technologies (HST) Programme offers a vital route for bringing ultra-rar...

Articles

08.10.2025

Orchestrating Evidence Needs: Overcoming Regulator...

Optimising evidence generation in trial design, while navigating regulatory and local payer requirem...

Articles

01.10.2025

MFN Drug Pricing Proposal: What It Could Mean for ...

Negotiations between the Trump administration and pharmaceutical companies on lowering U.S...

Articles

29.09.2025

Your 5-step ATMP pricing playbook for launch succe...

Advanced Therapy Medicinal Products (ATMPs) are offering transformative, and often life-saving, trea...

Articles

22.09.2025

ATMP Pricing in Practice: Success & Cautionary...

Advanced Therapy Medicinal Products (ATMPs) are leading in healthcare innovation, providing potentia...

Load more

Browse by topic

Advanced Therapy Medicinal Products
Alzheimer’s
BD Assessments
Biosimilars
Biotech
Devices & Diagnostics
Digital Health
Early Access
Early Payer Dialogue
Emerging & Developing Markets
Funding
Gene Therapy & ATMPs
HTA
International Reference Pricing
Launch
Managed Entry Agreements
Medicine manufacturing
MFN
NICE
Oncology
Orphan Drugs
PMA Trends
Pricing
Rare Diseases
Real World Evidence
Team Remap
Tendering & Procurement
Training
United States

Content type

All
Articles
Case Studies
Checklist
Guide
Insider Insights
News
Publications
Webinar

Subscribe